FDA-Approved Mpox Vaccine Now Commercially Available in the US


Bavarian Nordic's JYNNEOS available to healthcare providers nationwide.

mpox vaccine | Image credits: unsplash

Jynneos, the FDA-approved vaccine for mpox, is now available for commercial purchase in the United States. Healthcare providers can order the vaccine through wholesalers and distribution partners, making it accessible at pharmacies, physician offices, and public health clinics.

Initiated in 2022 in response to the global mpox outbreak, the vaccine's distribution was supported by Bavarian Nordic’s partnership with the US government, which supplied the vaccine for the national stockpile. The Centers for Disease Control and Prevention (CDC) provided interim guidance for the vaccine's use in at-risk individuals during the outbreak. In October 2023, the CDC's Advisory Committee on Immunization Practices (ACIP) recommended Jynneos for routine use in individuals 18 and older with certain risk factors.

Key Takeaways

  1. The JYNNEOS vaccine, used for preventing mpox is now commercially available in the United States.
  2. Following the mpox outbreak, the CDC's ACIP recommended JYNNEOS for routine use in individuals 18 and older with certain risk factors.
  3. The disease persists with around 200 cases reported monthly across most states in 2024.

“From the beginning of the mpox outbreak, almost 2 years ago, the prompt availability of an approved vaccine combined with a strong public health response have helped to significantly reduce the impact of this debilitating disease, but unfortunately, mpox has not gone away completely. Building on the trust and reliability as a supplier of vaccines to the US government for more than a decade, we are proud to extend our commitment to improving the nation’s public health by making our mpox vaccine widely available to at-risk individuals through the regular channels. We look forward to working with healthcare providers across the nation to increase awareness and availability of the mpox vaccine,”1 Paul Chaplin, President, and Chief Executive Officer of Bavarian Nordic.

The CDC estimates 2 million individuals in the US are eligible for the mpox vaccination. Recent data indicate that 60% of this population remains unvaccinated, and 15% have received only one dose of the vaccine. Evidence shows that 2 doses of Jynneos provide better protection against mpox, compared to one dose or no vaccination.

Adverse reactions to Jynneos can include severe allergic reactions, fainting, and a diminished immune response in immunocompromised persons. Common adverse reactions in smallpox vaccine-naïve adults include pain, redness, swelling, induration, and itching at the injection site, as well as muscle pain, headache, fatigue, nausea, and chills. Serious adverse events and cardiac adverse events of special interest have been reported but are rare.

Despite mpox no longer being considered a public health emergency, around 200 cases are reported monthly in the US, with transmission reported in most states in 2024. More than 32,000 cases have been reported in the US since the outbreak began in 2022.

The commercial availability of Jynneos through Bavarian Nordic's distribution structure aims to increase vaccine access for eligible individuals across the nation.


Bavarian nordic. BAVARIAN NORDIC ANNOUNCES COMMERCIAL LAUNCH OF MPOX VACCINE IN THE U.S. Published April 2, 2024. Accessed April 2, 2024. https://www.bavarian-nordic.com/media/media/news.aspx?news=6931

Related Videos
© 2024 MJH Life Sciences

All rights reserved.